Skip to main content
SpringerLink
Log in

The Management of HIV-Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1543 Accesses

Abstract

Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies – Kaposi’s sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bonnet F, Burty C, Lewden C et al (2009) Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 survey. Clin Infect Dis 48(5):633–639

    Article  PubMed  Google Scholar 

  2. Bohlius J, Schmidlin K, Costagliola D et al (2009) Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 23:2029–2037

    Article  PubMed  Google Scholar 

  3. Engels EA, Pfeiffer RM, Goedert JJ et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20:1645–1654

    Article  PubMed  Google Scholar 

  4. Powles T, Robinson D, Stebbing J et al (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27(6):884–890

    Article  PubMed  Google Scholar 

  5. Errante D, Gabarre J, Ridolfo AL et al (1999) Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 10:189–195

    Article  CAS  PubMed  Google Scholar 

  6. Grogg KL, Miller RF, Dogan A (2007) HIV infection and lymphoma. J Clin Pathol 60:1365–1372

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Tirelli U, Errante D, Dolcetti R et al (1995) Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and tumors. J Clin Oncol 13:1758–1767

    CAS  PubMed  Google Scholar 

  8. Howlader N, Noone AM, Krapcho M et al (eds) SEER cancer statistics review, 1975–2011. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014

  9. Biggar RJ, Horm J, Goedert JJ et al (1987) Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 126:578–586

    CAS  PubMed  Google Scholar 

  10. Hessol NA, Katz MH, Liu JY et al (1992) Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med 117:309–311

    Article  CAS  PubMed  Google Scholar 

  11. Serraino D, Carbone A, Franceschi S et al (1993) Increased frequency of lymphocyte depletion and mixed cellularity subtypes of Hodgkin disease in HIV-infected patients. Italian Cooperative Group on AIDS and Tumours. Eur J Cancer 29A:1948–1950

    Article  CAS  PubMed  Google Scholar 

  12. Serraino D, Pezzotti P, Dorrucci M et al (1997) Cancer incidence in a cohort of human immunodeficiency virus seroconverters. HIV Italian Seroconverters Study Group. Cancer 79:1004–1008

    Article  CAS  PubMed  Google Scholar 

  13. Franceschi S, Dal Maso L, Arniani D et al (1998) Risk of cancer other than Kaposi sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 78:966–970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. International Collaboration on HIV and Cancer (2000) Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823–1830

    Article  Google Scholar 

  15. Grulich AE, Li Y, McDonald A et al (2002) Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 16:1155–1161

    Article  PubMed  Google Scholar 

  16. Dal Maso L, Franceschi S, Polesel J et al (2003) Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer 89:94–100

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Herida M, Mary-Krause M, Kaphan R et al (2003) Incidence of non AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447–3453

    Article  PubMed  Google Scholar 

  18. Clifford GM, Polesel J, Rickenbach M et al (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425–432

    Article  PubMed  Google Scholar 

  19. Biggar RJ, Jaffe ES, Goedert JJ et al (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108:3786–3791

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Serraino D, Piselli P, Busnach G et al (2007) Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 43:2117–2123

    Article  PubMed  Google Scholar 

  21. Engels EA, Biggar RJ, Hall HI et al (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187–194

    Article  CAS  PubMed  Google Scholar 

  22. Seaberg EC, Wiley D, Martínez-Maza O et al (2010) Cancer incidence in the Multicenter AIDS Cohort Study before and during the HAART era: 1984–2007. Cancer 116:5507–5516

    Article  PubMed Central  PubMed  Google Scholar 

  23. Franceschi S, Lise M, Clifford GM et al (2010) Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 103:416–422

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Bohlius J, Schmidlin K, Boué F et al (2011) HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ -cell lymphocytes. Blood 117:6100–6108

    Article  CAS  PubMed  Google Scholar 

  25. Guiguet M, Boué F, Cadranel J et al (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10:1152–1159

    Article  CAS  PubMed  Google Scholar 

  26. Lanky E, Rosenberg PS, Fily F et al (2011) HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 118:44–49

    Article  Google Scholar 

  27. Levine AM (2006) Hodgkin lymphoma: to the HAART of the matter. Blood 108:3630

    Article  CAS  Google Scholar 

  28. Gloghini A, Carbone A (2007) Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer 120:2753–2754

    Article  CAS  PubMed  Google Scholar 

  29. Carbone A, Cabras A, Gloghini A (2007) HIV-associated Hodgkin’s lymphoma. Antiapoptotic pathways and mechanisms for immune escape by tumor cells in the setting of improved immunity. Int J Biol Markers 22:161–163

    CAS  PubMed  Google Scholar 

  30. Dolcetti R, Boiocchi M, Gloghini A, Carbone A (2001) Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer 37(10):1276–1287

    Article  CAS  PubMed  Google Scholar 

  31. Said JW (2007) Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 14:189–194

    Article  PubMed  Google Scholar 

  32. Carbone A, Gloghini A, Larocca LM et al (1999) Human immunodeficiency virus associated Hodgkin’s disease derives from post-germinal center B cells. Blood 93:2319–2326

    CAS  PubMed  Google Scholar 

  33. Rezk SA, Weiss LM (2007) Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 38:1293–1304

    Article  CAS  PubMed  Google Scholar 

  34. Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13:577–585

    Article  PubMed  Google Scholar 

  35. Hentrich M, Berger M, Wyen C et al (2012) Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 30:4117–4123

    Article  PubMed  Google Scholar 

  36. Klein U, Dalla-Favera R (2008) Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 8:22–33

    Article  CAS  PubMed  Google Scholar 

  37. Vockerodt M, Morgan S, Kuo M et al (2008) The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin’s Reed-Sternberg-like phenotype. J Pathol 216(1):83–92

    Article  CAS  PubMed  Google Scholar 

  38. Landrieu JM, Roithmann S, Tourani JM et al (1993) Hodgkin’s disease during HIV-1 infection: the French registry experience. Ann Oncol 4:635–641

    Google Scholar 

  39. Rubio R (1994) Disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cancer 73:2400–2407

    Article  CAS  PubMed  Google Scholar 

  40. Montoto S, Shaw K, Okosun J et al (2012) HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 30:4111–4116

    Article  PubMed  Google Scholar 

  41. Ribera J-M, Navarro JT, Oriol A et al (2002) Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin’s disease. AIDS 16:1973–1976

    Article  PubMed  Google Scholar 

  42. Gérard L, Galicier L, Boulanger E et al (2003) Improved survival in HIV-related Hodgkin’s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17:81–87

    Article  PubMed  Google Scholar 

  43. Hoffmann C, Chow KU et al (2004) Strong impact of highly active antiretroviral therapy HIV-associated Hodgkin disease. Br J Haematol 125(4):455–462

    Article  PubMed  Google Scholar 

  44. Hentrich M, Maretta L, Chow KU et al (2006) Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin’s disease: results of a multicenter study. Ann Oncol 17:914–919

    Article  CAS  PubMed  Google Scholar 

  45. Chimienti E, Spina M, Gastaldi R et al (2008) Clinical characteristics and outcome of 290 patients (pts) with Hodgkin’s disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol 19:iv136, abstract 168

    Article  Google Scholar 

  46. Berenguer J, Miralles P, Ribera JM et al (2008) Characteristics and outcome of AIDS related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47:422–428

    Article  CAS  PubMed  Google Scholar 

  47. Spina M, Gabarre J, Rossi G et al (2002) Stanford V and concomitant HAART in 59 patients with Hodgkin’s disease and HIV infection. Blood 100:1984–1988

    Article  CAS  PubMed  Google Scholar 

  48. Spina M, Rossi G, Antinori A et al (2008) VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol 19:iv152, abstract 227

    Article  Google Scholar 

  49. Errante D, Tirelli U, Gastaldi R et al (1994) Combined antineoplastic and antiretroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer 73:437–444

    Article  CAS  PubMed  Google Scholar 

  50. Levine AM, Li P, Cheung T et al (2000) Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr 24:444–450

    Article  CAS  PubMed  Google Scholar 

  51. Gastaldi R, Martino P, Gentile G et al (2002) Hodgkin’s disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol 13(7):1158–1160

    Article  CAS  PubMed  Google Scholar 

  52. Hartmann P, Rehwald U, Salzberger B et al (2003) BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 14:1562–1569

    Article  CAS  PubMed  Google Scholar 

  53. Xicoy B, Ribera JM, Miralles P et al (2007) Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 92:191–198

    Article  CAS  PubMed  Google Scholar 

  54. Hentrich M, Hoffmann C, Mosthaf F et al (2014) Therapy of HIV-associated lymphoma – recommendations of the oncology working group of the German Study Group of Physicians in private practice treating HIV-infected patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). Ann Hematol 93:913–921

    Article  CAS  PubMed  Google Scholar 

  55. Cingolani A, Torti L, Pinnetti C et al (2010) Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS 24:2408–2412

    CAS  PubMed  Google Scholar 

  56. Ezzat HM, Cheung MC, Hicks LK et al (2012) Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma 53:2390–2396

    Article  CAS  PubMed  Google Scholar 

  57. Re A, Cattaneo C, Skert C et al (2013) Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica 98:1762–1768

    Article  PubMed Central  PubMed  Google Scholar 

  58. Re A, Cattaneo C, Michieli M et al (2003) High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 21:4423–4427

    Article  CAS  PubMed  Google Scholar 

  59. Gabarre J, Marcelin AG, Azar N et al (2004) High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 89:1100–1108

    PubMed  Google Scholar 

  60. Krishnan A, Molina A, Zaia J et al (2005) Durable remission with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105:874–878

    Article  CAS  PubMed  Google Scholar 

  61. Serrano D, Carrion R, Balsalobre P et al (2005) HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 33:487–494

    Article  CAS  PubMed  Google Scholar 

  62. Spitzer TR, Ambinder RF, Lee JY et al (2008) Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transplant 14:59–66

    Article  CAS  PubMed  Google Scholar 

  63. Balsalobre P, Diez-Martin JL, Re A et al (2009) Autologous stem cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 27:​2192–2198

    Article  PubMed  Google Scholar 

  64. Re A, Michieli M, Casari S et al (2009) High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114(7):1306–1313

    Article  CAS  PubMed  Google Scholar 

  65. Diez-Martin JL, Balsalobre P, Re A et al (2009) Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113:6011–6014

    Article  CAS  PubMed  Google Scholar 

  66. Simonelli C, Zanussi S, Pratesi C et al (2010) Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma. Clin Infect Dis 50:1672–1679

    Article  CAS  PubMed  Google Scholar 

  67. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  68. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578

    Article  PubMed  Google Scholar 

  69. Gallamini A, Rigacci L, Merli F et al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91(4):475–481

    PubMed  Google Scholar 

  70. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59

    Article  CAS  PubMed  Google Scholar 

  71. Just PA, Fieschi C, Baillet G et al (2008) 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDs 22(9):695–700

    Article  PubMed  Google Scholar 

  72. Goshen E, Davidson T, Avigdor A et al (2008) PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 33(9):610–614

    Article  PubMed  Google Scholar 

  73. Okosun J, Warbey Shaw K et al (2012) Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV-infection. AIDS 26:861–865

    Article  CAS  PubMed  Google Scholar 

  74. Sathekge M, Maes A, Kgomo M, Van de Wiele C (2010) Fluorodeoxyglucose uptake by lymph nodes of HIV patients is inversely related to CD4 count. Nucl Med Commun 31:137–140

    Article  PubMed  Google Scholar 

  75. Sathekge M, Maes A, Kgomo M et al (2010) FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging 54:698–703

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology A, National Cancer Institute, Via Franco Gallini 2, Aviano, PN, 33081, Italy

    Michele Spina MD & Umberto Tirelli

  2. Department of Hematology-Oncology, Harlaching Hospital, University of Munich, Sanatoriumsplatz 2, Munich, 81545, Germany

    Marcus Hentrich

Authors
  1. Michele Spina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Hentrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umberto Tirelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Spina MD .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Spina, M., Hentrich, M., Tirelli, U. (2015). The Management of HIV-Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation